Celldex Therapeutics, Inc. Revenue
Celldex Therapeutics, Inc. (CLDX) reported Revenue of $22.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-06
- Celldex Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $22.00K, a 96.99% decline year-over-year.
- Celldex Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $15.00K, a 97.84% decline year-over-year.
- Celldex Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $121.00K, a 89.70% decline year-over-year.
- Celldex Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Celldex Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $1.54M, a 77.99% decline from fiscal 2024.
- Celldex Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $7.02M, a 1.99% increase from fiscal 2023.
- Celldex Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $6.88M, a 192.02% increase from fiscal 2022.
- Celldex Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $2.36M, a 49.32% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $22.00K 10-Q · filed 2026-08-06 | $37.00K 10-Q · filed 2026-08-06 | $158.00K derived: sum of 3 quarters · filed 2026-08-06 | $158.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $15.00K 10-Q · filed 2026-05-07 | $136.00K derived: sum of 2 quarters · filed 2026-05-07 | $136.00K derived: sum of 3 quarters · filed 2026-05-07 | $866.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $121.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $121.00K derived: sum of 2 quarters · filed 2026-02-25 | $851.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.54M 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $730.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.42M 10-Q · filed 2025-11-10 | $2.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $730.00K 10-Q · filed 2026-08-06 | $1.42M 10-Q · filed 2026-08-06 | $2.60M derived: sum of 3 quarters · filed 2026-08-06 | $5.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $695.00K 10-Q · filed 2026-05-07 | $1.87M derived: sum of 2 quarters · filed 2026-05-07 | $5.06M derived: sum of 3 quarters · filed 2026-05-07 | $7.56M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.37M derived: sum of 2 quarters · filed 2026-02-25 | $6.86M derived: sum of 3 quarters · filed 2026-02-25 | $7.02M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.19M 10-Q · filed 2025-11-10 | $5.69M derived: sum of 2 quarters · filed 2025-11-10 | $5.84M 10-Q · filed 2025-11-10 | $9.98M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $2.50M 10-Q · filed 2025-08-07 | $2.65M 10-Q · filed 2025-08-07 | $6.79M derived: sum of 3 quarters · filed 2026-02-25 | $8.30M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $156.00K 10-Q · filed 2025-05-08 | $4.29M derived: sum of 2 quarters · filed 2026-02-25 | $5.80M derived: sum of 3 quarters · filed 2026-02-25 | $6.07M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $5.65M derived: sum of 2 quarters · filed 2026-02-25 | $5.92M derived: sum of 3 quarters · filed 2026-02-25 | $6.88M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.52M 10-Q · filed 2024-11-06 | $1.78M derived: sum of 2 quarters · filed 2024-11-06 | $2.75M 10-Q · filed 2024-11-06 | $4.37M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $268.00K 10-Q · filed 2024-08-08 | $1.23M 10-Q · filed 2024-08-08 | $2.85M derived: sum of 3 quarters · filed 2025-02-27 | $3.25M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $967.00K 10-Q · filed 2024-05-06 | $2.58M derived: sum of 2 quarters · filed 2025-02-27 | $2.99M derived: sum of 3 quarters · filed 2025-02-27 | $3.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $2.02M derived: sum of 2 quarters · filed 2025-02-27 | $2.18M derived: sum of 3 quarters · filed 2025-02-27 | $2.36M 10-K · filed 2025-02-27 |
| 2022-09-30 | $407.00K 10-Q · filed 2023-11-02 | $570.00K derived: sum of 2 quarters · filed 2023-11-02 | $744.00K 10-Q · filed 2023-11-02 | $1.08M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $163.00K 10-Q · filed 2023-08-08 | $337.00K 10-Q · filed 2023-08-08 | $671.00K derived: sum of 3 quarters · filed 2024-02-26 | $824.00K derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $174.00K 10-Q · filed 2023-05-04 | $508.00K derived: sum of 2 quarters · filed 2024-02-26 | $661.00K derived: sum of 3 quarters · filed 2024-02-26 | $4.14M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $487.00K derived: sum of 2 quarters · filed 2024-02-26 | $3.97M derived: sum of 3 quarters · filed 2024-02-26 | $4.65M 10-K · filed 2024-02-26 |
| 2021-09-30 | $153.00K 10-Q · filed 2022-11-09 | $3.63M derived: sum of 2 quarters · filed 2022-11-09 | $4.32M 10-Q · filed 2022-11-09 | $8.10M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $3.48M 10-Q · filed 2022-08-08 | $4.17M 10-Q · filed 2022-08-08 | $7.95M derived: sum of 3 quarters · filed 2022-08-08 | $8.62M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $685.00K 10-Q · filed 2022-05-05 | $4.47M derived: sum of 2 quarters · filed 2022-05-05 | $5.14M derived: sum of 3 quarters · filed 2022-05-05 | $5.38M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $3.79M 10-K · filed 2021-03-29 | $4.45M derived: sum of 2 quarters · filed 2021-11-09 | $4.69M derived: sum of 3 quarters · filed 2021-11-09 | $7.42M 10-K · filed 2023-02-28 |
| 2020-09-30 | $668.00K 10-Q · filed 2021-11-09 | $904.00K derived: sum of 2 quarters · filed 2021-11-09 | $3.63M 10-Q · filed 2021-11-09 | $4.52M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $236.00K 10-Q · filed 2021-08-05 | $2.96M 10-Q · filed 2021-08-05 | $3.85M derived: sum of 3 quarters · filed 2021-08-05 | $4.40M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $2.73M 10-Q · filed 2021-05-06 | $3.62M derived: sum of 2 quarters · filed 2021-05-06 | $4.16M derived: sum of 3 quarters · filed 2021-05-06 | $4.88M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $887.00K 10-K · filed 2021-03-29 | $1.43M derived: sum of 2 quarters · filed 2021-03-29 | $2.15M derived: sum of 3 quarters · filed 2021-03-29 | $3.57M 10-K · filed 2022-02-28 |
| 2019-09-30 | $546.00K 10-K · filed 2021-03-29 | $1.26M derived: sum of 2 quarters · filed 2021-03-29 | $2.69M 10-Q · filed 2020-11-05 | $4.45M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-06-30 | $715.00K 10-K · filed 2021-03-29 | $2.14M 10-Q · filed 2020-08-06 | $3.90M derived: sum of 3 quarters · filed 2021-03-29 | $4.84M derived: sum of 4 quarters · filed 2021-03-29 |
| 2019-03-31 | $1.43M 10-K · filed 2021-03-29 | $3.19M derived: sum of 2 quarters · filed 2021-03-29 | $4.13M derived: sum of 3 quarters · filed 2021-03-29 | $6.89M derived: sum of 4 quarters · filed 2021-03-29 |
| 2018-12-31 | $1.76M 10-K · filed 2020-03-26 | $2.71M derived: sum of 2 quarters · filed 2020-03-26 | $5.47M derived: sum of 3 quarters · filed 2020-03-26 | $9.54M 10-K · filed 2021-03-29 |
| 2018-09-30 | $941.00K 10-K · filed 2020-03-26 | $3.70M derived: sum of 2 quarters · filed 2020-03-26 | $7.77M 10-Q · filed 2019-11-12 | $11.23M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $2.76M 10-K · filed 2020-03-26 | $6.83M 10-Q · filed 2019-08-07 | $10.29M derived: sum of 3 quarters · filed 2020-03-26 | $14.21M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | $4.07M 10-K · filed 2020-03-26 | $7.52M derived: sum of 2 quarters · filed 2020-03-26 | $11.45M derived: sum of 3 quarters · filed 2020-03-26 | $15.28M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | $3.46M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $7.38M derived: sum of 2 quarters · filed 2020-03-26 | $11.21M derived: sum of 3 quarters · filed 2020-03-26 | $12.74M 10-K · filed 2020-03-26 |
| 2017-09-30 | $3.92M 10-Q · filed 2018-11-07 | $7.75M derived: sum of 2 quarters · filed 2018-11-07 | $9.29M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $3.83M 10-Q · filed 2018-08-08 | $5.36M 10-Q · filed 2018-08-08 | ||
| 2016-12-31 | $6.79M 10-K · filed 2019-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |